EpiCept Corporation Merges With Immune Pharmaceuticals

Immune develops next-generation antibodies
Immune is a privately held Israeli biopharmaceutical company focused on the development of antibody therapeutics for treating inflammatory diseases and cancer. Its lead product, bertilimumab (previously CAT-213), is licensed for non-ophthalmic indications from the Canadian biotech iCo Therapeutics (and originated at Cambridge Antibody Technology in the UK). Immune also has a technology, NanomAbs, for generating antibody drug conjugates, in preclinical studies.